- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...

In September 1970, Janet Mertz joined the biochemistry department at Stanford University. She was one of only six new graduate students in the department and the first female one admitted in nine ...

Gene therapy holds the promise of preventing and curing disease by manipulating gene expression within a patient's cells. However, to be effective, the new gene must make it into a cell's nucleus. The ...

Transfection, a key genetic technology in the toolbox of many researchers, spans numerous applications—production of recombinant proteins and recombinant cell lines, drug discovery, delivery of ...

Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...

Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

A new study in the journal Human Gene Therapy indicates that DNA impurities derived from plasmid and host cell DNA are encapsulated into recombinant adeno-associated virus (rAAV) capsids as ...

The AI2Health cluster of the Ken Kennedy Institute and the Synthetic Biology Institute at Rice University hosted a debriefing and collaborative discussion session on the Spirit of Asilomar summit June ...